Keyword: Amal Therapeutics

German pharma Boehringer Ingelheim is putting a few hundred million euros on the table to snap up Swiss cancer biotech Amal Therapeutics.

Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.